Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients
B Uncu Ulu, MS Dal, İ Yönal Hindilerden… - Journal of …, 2022 - Taylor & Francis
The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL)
patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used …
patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used …
[引用][C] Time to change direction in the treatment of relapsed Hodgkin lymphoma?
M Crump - Journal of Clinical Oncology: Official Journal of the …, 2020 - europepmc.org
Time to Change Direction in the Treatment of Relapsed Hodgkin Lymphoma? - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …